PSCA CAR Vδ1 T cells: a safer off-the-shelf CAR T therapy for pancreatic cancer? Authors: Joseph A Fraietta, Jason J Lohmueller Published: 2026 ABSTRACT AbstractPancreatic cancer remains among the deadliest malignancies, with a 5-year survival of ~13%. Chimeric antigen receptor (CAR) T -cell therapy offers hope, but conventional αβ T cells can trigger severe toxicities, including graft-versus-host disease (GvHD) when used for allogeneic therapy. By contrast, γδ T cells recognize tumors without MHCmajor histocompatibility complex restriction and are unlikely to cause GvHD, making them attractive candidates for “off-the-shelf” immunotherapy. Li et al engineered the Vδ1 subset of γδ T cells with a CAR targeting prostate stem cell antigen (PSCA) and compared these cells to CAR-engineered Vδ2 γδ and conventional αβ T cells in preclinical pancreatic cancer models. All three groups showed comparable tumor killing efficacy, but the CAR Vδ1 T cells induced none of the GvHD or systemic toxicity seen with CAR αβ T cells. They also displayed lower exhaustion than CAR Vδ2 cells, suggesting potential for greater persistence. Vδ1 CAR T cells could be expanded robustly ex vivo and remained highly potent even after cryopreservation, a key “off-the-shelf” requirement. These findings position CAR Vδ1 T cells as a safer alternative to traditional CAR T cells. Future rigorous clinical evaluation will be needed to confirm superior safety and efficacy of this promising approach in patients.Keywords: Chimeric antigen receptor - CAR, Gastrointestinal Cancer, Graft versus host disease - GVHD, Immunotherapy, T cell Pancreatic cancer (PC) is notorious for its poor prognosis, with a mere 13% 5-year survival rate.1 Unlike leukemias and lymphomas, where chimeric antigen receptor (CAR) T therapies have achieved remarkable success, solid tumors like PC remain difficult targets.2 One major hurdle is toxicity. Conventional CAR T cells derived from αβ T lymphocytes can cause life-threatening complications, including graft-versus-host disease (GvHD) (if donor-derived) and cytokine release syndrome (CRS).3 These risks, along with the immunosuppressive tumor microenvironment, have limited the translational impact of CAR T cells in cancers such as PC.4 γδ T cells have emerged as a compelling alternative for cellular immunotherapy.5 These unconventional T cells combine features of innate and adaptive immunity, recognizing stress-induced ligands on tumors without the need for antigen presentation by major histocompatibility complex (MHC) molecules (reviewed in6). Critically, γδ T cells do not target allogeneic human leukocyte antigens, so they are far less prone to mediating GvHD even when coming from unmatched donors. This inherent safety advantage positions γδ T cells as ideal vehicles for allogeneic “off-the-shelf” therapies.5 Among γδ T cells, the Vδ1-expressing subset predominantly resides in tissues (including epithelial tumors), whereas Vδ2 T cells circulate in peripheral blood. The tissue tropism of Vδ1 γδ T cells suggests they might be especially effective in homing to solid tumor environments. However, Vδ1 cells are rare in blood and historically difficult to expand, so their therapeutic potential has been underexplored.6 Until now, most γδ T -cell trials have used the more abundant Vδ2 T cells, with modest results.5 Li et al7 tackled the challenge head-on by developing a CAR-targeted at prostate stem cell antigen (PSCA), a cell-surface antigen frequently overexpressed in pancreatic adenocarcinoma. They engineered this CAR into human Vδ1 γδ T cells and achieved robust ex vivo expansion of the otherwise scarce Vδ1 population. In a head-to-head comparison, the authors evaluated PSCA CAR-engineered Vδ1 cells alongside CAR Vδ2 γδ T cells and conventional CAR αβ T cells, in functional assays. Notably, all three CAR T -cell types demonstrated comparable antitumor activity against PSCA+ PC cells. The CAR Vδ1 T cells were just as potent in killing tumor targets as the familiar CAR αβ T cells, indicating no sacrifice of efficacy when using γδ T cells. This finding is noteworthy because it shows that the less common Vδ1 subset can mount tumor cytotoxicity on par with both mainstream αβ T cells and the Vδ2 subset, at least in controlled models. Where the Vδ1 CAR T cells truly distinguished themselves was in safety.7 In immunodeficient mouse models engrafted with human tumors, CAR αβ T cells readily caused GvHD, as expected from their alloreactivity. In contrast, mice treated with PSCA CAR Vδ1 T cells showed no signs of GvHD or cytokine storm, with clinical scores indistinguishable from untreated controls and far better than the CAR αβ T -cell group. The Vδ1 T cells thus lived up to the immunological promise of γδ cells by attacking the tumor without attacking the host. It is also notable that the CAR-modified Vδ1 cells did not trigger the systemic inflammatory responses that underlie severe CRS. This may be partly due to the different cytokine profiles of γδ T cells, but it aligns with early clinical observations that γδ T -cell therapies tend to be better tolerated than αβ T -cell therapies. The implication is powerful because an allogeneic CAR T -cell product could be given safely to any patient, without the need for patient-specific manufacturing or heavy immunosuppression to prevent GvHD. Another important finding by Li et al7 relates to T -cell exhaustion. Repeated antigen exposure often drives CAR T cells into a dysfunctional, “exhausted” state, especially in solid tumor settings. Using single-cell RNA sequencing, the authors found that PSCA CAR Vδ1 T cells had significantly lower expression of exhaustion markers compared with CAR Vδ2 T cells.7 This result echoes prior reports that tissue-resident Vδ1 T cells can retain function even when expressing exhaustion markers.8 9 For therapy, this could mean CAR Vδ1 T cells persist and continue fighting longer than other γδ T -cell types. A durable effector population is especially crucial in PC, where tumors are adept at suppressing immune cells. While the exact mechanisms remain to be clarified, Vδ1 cells may have intrinsic transcriptional programs that confer greater stamina. If this lower exhaustion translates to better in vivo persistence, it would further enhance the therapeutic potential of CAR Vδ1 cells over current alternatives. From a translational perspective, a key advance of this study7 is the demonstration that CAR Vδ1 T cells can be produced at scale and cryopreserved without losing functionality. Both fresh and thawed CAR Vδ1 cells exhibited comparable cytotoxicity in vitro and in vivo. This means a batch of Vδ1 CAR T cells could be manufactured from a healthy donor, banked, and shipped frozen to treat multiple patients on demand, the paradigm of an “off-the-shelf” cell therapy (figure 1). Achieving this was non-trivial, given the historical difficulty in expanding Vδ1 T cells. Li et al7 optimized culture conditions (including feeder cells and cytokines) to selectively propagate Vδ1 T cells from peripheral blood, reaching the scale needed for therapy. The resulting cell product was >95% pure Vδ1 T cells and genetically modified with the CAR, plus a safety switch (truncated epidermal growth factor receptor (EGFR)) for potential clinical use. The ability to bank these cells adds a practical translational edge to the approach because it moves CAR T therapy a step closer to an allogeneic model similar to how we transfuse donor blood or give bone marrow transplants, rather than a bespoke autologous treatment. This is especially relevant for aggressive cancers like PC, where patients may not have weeks to wait for a personalized cell product. Operationally, this is still an approximately 3–4 weeks process: donor peripheral blood mononuclear cells (PBMCs) undergo 14–21 days of γδ enrichment, Vδ1 cells are then flow-sorted, re-expanded with weekly irradiated K562 feeder cells, activated for 48 hours, subjected to retroviral vector-mediated CAR transfer, further expanded, and finally cryopreserved for later use.8 That feeder-supported, retroviral workflow is important practical context for future Good Manufacturing Practices (GMP) translation and cost modeling. Workflow for “off-the-shelf” PSCA CAR-Vδ1 γδ T cells. Schematic summarizes the allogeneic manufacturing concept evaluated by Li et al. Peripheral blood mononuclear cells (PBMCs) from a healthy donor are enriched for Vδ1 γδ T cells, expanded, and transduced with a retroviral vector encoding a PSCA-specific chimeric antigen receptor (CAR) linked to a truncated EGFR (tEGFR) safety marker. The CAR+ Vδ1 γδ T cells are further expanded, vialed, and cryopreserved to generate an off-the-shelf product that can be thawed for treatment of multiple recipients with PSCA+ pancreatic cancer. Figure generated with BioRender.com. Approximate day annotations are included to indicate the overall engineering timeline, with γδ enrichment over 14–21 days followed by Vδ1 sorting, feeder-supported expansion, activation, retroviral transduction, and cryopreservation. Weekly irradiated K562 feeder-cell support is shown explicitly in the revised schematic. CAR, chimeric antigen receptor; EGFR, epidermal growth factor receptor; PBMC, peripheral blood mononuclear cell; PSCA, prostate stem cell antigen; tEGFR, truncated EGFR. While Li et al7 showcase a compelling proof-of-concept, the preclinical context leaves key translational questions unanswered. All efficacy and safety data were obtained in NSG mice lacking a fully immunocompetent tumor microenvironment, so it remains unclear how PSCA CAR Vδ1 γδ T cells will perform under the immunosuppressive pressures and antigen heterogeneity of human pancreatic tumors. For example, CAR Vδ1 cells exhibited significantly lower exhaustion marker expression than their Vδ2 counterparts by transcriptomic analysis, but the authors acknowledge that this putative durability advantage must be confirmed in more physiologic models. Similarly, PSCA is not uniformly expressed in PC (ie, present in 60–80% of tumors), and it is uncertain whether the innate tumor-recognition mechanisms of Vδ1 T cells can compensate for antigen‐negative escape, particularly since those non-CAR interactions appeared to play only a minimal role in this model. While receptors such as NKG2D, DNAM-1, and NKp30 were found to be up-regulated, blocking them on CAR Vδ1 cells in co-culture assays did not affect cytotoxicity. These gaps are all addressable, and they point to logical next steps such as evaluating CAR Vδ1 cells in immunocompetent or patient-derived models and elucidating Vδ1 T-cell receptor ligand interactions, to ensure this promising therapy can overcome tumor microenvironmental barriers and antigen escape in patients. A useful intermediate step would be donor-matched PBMC-humanized dual-MHC-knockout NSG mice, which attenuate xenogeneic GvHD while preserving human T-cell function and extend the window for testing residual alloreactivity and inflammatory toxicity.10 In summary, Li et al7 have provided evidence that Vδ1 γδ T cells can be engineered into potent CAR T cells for solid tumor therapy without the usual safety liabilities. Their PSCA-targeted CAR Vδ1 cells matched the antitumor efficacy of conventional CAR T cells while avoiding GvHD and CRS, and showed signs of greater durability via reduced exhaustion. Equally important, the study established methods to expand and preserve these cells, supporting the feasibility of an “off-the-shelf” allogeneic product. Taken together, the work positions PSCA CAR Vδ1 T cells as a promising new modality for PC immunotherapy, potentially an equally efficacious but safer alternative to CAR αβ T cells. This strategy exemplifies the broader push in the field toward universal cell therapies that can be delivered readily and safely to patients. Of course, the true test will be in clinical trials. Early clinical results with Vδ1 γδ CAR T cells targeting CD20 for relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma have shown limited toxicities with an absence of GvHD, as well as promising persistence and efficacy. Questions remain about how these cells will perform in the immunosuppressive human solid tumor microenvironment and whether their advantages will translate into meaningful patient outcomes. Nonetheless, this study is an encouraging step forward. It highlights how harnessing the unique biology of Vδ1 γδ T cells could overcome some of the long-standing barriers in CAR T therapy. The path is now set for early-phase trials to evaluate whether PSCA CAR Vδ1 T cells can indeed fulfill the promise as a safe, “off-the-shelf” treatment against one of the hardest-to-treat cancers. Footnotes Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. Patient consent for publication: Not applicable. Ethics approval: Not applicable. Provenance and peer review: Not commissioned; externally peer reviewed. Author note: Joseph Fraietta, LinkedIn @ joseph-fraietta-2b771b158; Jason Lohmueller, LinkedIn @ jason-lohmueller-1663b551 References